NASDAQ:Rocket Pharmaceuticals, Inc.

График котировок Rocket Pharmaceuticals, Inc.

Добавить в список сравнения Добавить в список сравнения
Добавить в список отслеживания Добавить в список отслеживания
Добавить в портфель Добавить в портфель

Основные параметры

P/BV 13.84
EV/EBITDA -34.99
EBITDA -0.09
Цена ао 55.05

Основные владельцы

Institutions Объем Доля, %
RTW INVESTMENTS, LLC 16812491 28.08
Global X Management Company LLC 80583 0.13
Ghost Tree Capital, LLC 400000 0.67
Putnam Investment Management, LLC 603960 1.01
Voya Investments, LLC 145207 0.24
Arctic Asset Management AS 67146 0.11
Osterweis Capital Management LLC 88885 0.15
Allianz Global Investors U.S. LLC 16063 0.03
Federated MDTA LLC 373055 0.62
Cormorant Asset Management, LLC 1368550 2.29
Boxer Capital LLC 1466051 2.45
Vivo Capital, LLC 860648 1.44
Voya Investment Management Co. LLC (US) 112018 0.19
AXA Investment Managers Paris 7049 0.01
HBM Partners Cayman Ltd 950000 1.59
AXA Investment Managers UK Ltd 210906 0.35
Brighthouse Investment Advisers, LLC 170533 0.31
Allianz Global Investors GmbH 59663 0.1

Содержится в ETF

ETF Доля, % Доходность за год, %
PGIM QMA Strategic Alpha Small-Cap Growth ETF 0.34 22.67

Похожие компании

Описание Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has clinical-stage lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction, and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. It also has additional infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption. In addition, the company has an adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO Inc. The company also has a research and collaboration agreement with Lund University; and strategic collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc. is headquartered in New York, New York.